Immunotherapy in Glioblastoma: Why Has Progress Been so Difficult?
TL;DR
This review summarizes the main immunotherapeutic approaches currently investigated, including immune checkpoint inhibitors, CAR-T cell therapy, cancer vaccines, and oncolytic viruses, and examines the key biological factors responsible for treatment resistance.
Abstract
Glioblastoma remains one of the most aggressive and difficult-to-treat brain tumors. Although immunotherapy has transformed the management of several cancers, its clinical impact in glioblastoma has been limited. This review summarizes the main immunotherapeutic approaches currently investigated, including immune checkpoint inhibitors, CAR-T cell therapy, cancer vaccines, and oncolytic viruses. It also examines the key biological factors responsible for treatment resistance. Major challenges include the highly immunosuppressive tumor microenvironment, tumor heterogeneity, antigen escape, low immunogenicity, and the presence of the blood–brain barrier. These factors restrict effective antitumor immune responses and reduce the efficacy of current therapies. Emerging strategies focusing on the tumor microenvironment, cytokine-based treatments, personalized medicine, and rational combination approaches may improve future outcomes. A deeper understanding of glioblastoma biology will be essential for the development of effective and individualized immunotherapeutic strategies.